Navigation Links
Cephalon Shareholders Approve Acquisition by Teva
Date:7/14/2011

FRAZER, Pa., July 14, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its stockholders voted to approve the Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion.

The transaction remains under review by the U.S. Federal Trade Commission and the European Commission.  Cephalon and Teva continue to operate as two independent companies pending those clearances.  

About Cephalon

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 170 products in nearly 100 countries. More information on Cephalon and its products is available at http://www.cephalon.com/.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide the Cephalon current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Contacts:

Media:

Fritz Bittenbender
610-883-5855 (office)
610-457-7041 (cell)
fbittenb@cephalon.com

Natalie de Vane
610-727-6536 (office)
610-999-8756 (cell)
ndevane@cephalon.com

Investor Relations:

Chip Merritt
610-738-6376 (office)
cmerritt@cephalon.com

Joseph Marczely
610-883-5894 (office)
jmarczely@cephalon.com


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... Feb. 23, 2017  Genesis Healthcare Services has merged ... was made by Bill Monast , President and ... and Nathan Feltman , executives with Home Health ... LLC. This acquisition helps Hospice Cloud ... technology enabled durable medical equipment (DME) solutions for the ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified healthcare company, ... 31 December 2016 compared with the previous corresponding period. A full ... here . Highlights Profit ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; ... up 11%) Profit before tax of $2.12m (Dec ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is ... KLS is a longtime supporter of the event. , "We are pleased that ... said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... “Doping in Sport: How the Culture Might Change,” in conjunction with ... symposium will be held at Pepperdine University in Malibu, California. , Sir Philip ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... pre-eminent publication and community for those in the fight against cancer, has produced ... in their success. HRA will release top-line findings in a webinar, Defining ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Curemark, LLC ... safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling ... sites already enrolling children across the United States. , “There are currently no ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and athletics. It’s enough to overwork even the sharpest brain. , Power On, ... peak healthy activity without over clocking the brain. Each capsule contains Cognizin® Citicoline, ...
Breaking Medicine News(10 mins):